From GlobeNewswire: 2025-04-01 16:49:00

BioStem Technologies, Inc. has filed for an extension to submit its annual report for the year ended December 31, 2024 to the OTC due to a mandatory SEC review process. The company anticipates filing the report by April 15, which marks the end of the extension period. CEO Jason Matuszewski expressed gratitude for shareholders’ patience and announced a webcast to cover fourth quarter and year-end 2024 results. BioStem Technologies specializes in placental-derived products for advanced wound care and is focused on developing life-changing products. The company’s quality management system is accredited by the American Association of Tissue Banks (AATB), and its allografts are processed in Pompano Beach, Florida.



Read more at GlobeNewswire: BioStem Technologies Announces Extension to File 2024